Question 1

Research Studies

Accepted Answer

Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2017). Efficacy and Safety of Once-Weekly Semaglutide versus Exenatide ER in subjects with Type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, randomized clinical trial. Diabetes Care, 41(2), 258–266. https://doi.org/10.2337/dc17-0417
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. Diabetes & Endocrinology, 7(10), 776–785. https://doi.org/10.1016/s2213-8587(19)30249-9
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism, 19(9), 1242–1251. https://doi.org/10.1111/dom.12932
Urva, S., O’Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023b). The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism, 25(9), 2784–2788. https://doi.org/10.1111/dom.15167

Question 2

References

Accepted Answer

Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023). Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism, 25(1), 18–35. https://doi.org/10.1111/dom.14863

Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28, 2083–2091. https://doi.org/10.1038/s41591-022-02026-4

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232.
https://doi.org/10.1056/NEJMoa2307563

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New
England Journal of Medicine, 384(11), 989–1002.
https://doi.org/10.1056/NEJMoa2032183

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., ... & Vilsbøll, T. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844.
https://doi.org/10.1056/NEJMoa1607141

February Savings are Here! Click Here for Current Promos.

Information for GLP-1-S

GMP Certificates of Analysis

Older GMP Certificates of Analysis

Research Certificates of Analysis

Older Research Certificates of Analysis

GLP-1-S Peptide Structure

Product Usage

Related Products

PCL Reconstitution Solution – 5 mL

PCL GLP-2-T 60mg

PCL GLP-2-T 10mg

GMP GLP-2-T 15mg

PCL GLP-2-T 30mg

GMP GLP-2-T 30mg

PCL GLP-2-T 15mg

Combo Pack – GLP-1-S, Cagrilintide & Reconstitution Solution

Get In Touch!

Additional Resources

About PekCura